Method for inducing bronchodilation using optically pure R(-) albuterol

• US 5,844,002 A
• Filed: 04/21/1998
• Issued: 12/01/1998
• Est. Priority Date: 01/05/1990
• Status: Expired due to Fees

• Current Assignee: Sepracor Incorporated
• Original Assignee: Sepracor Incorporated
• Inventors: Barberich, Timothy J., Young, James W.
• Primary Examiner(s): HENLEY III, RAYMOND J
• Application Number:
  US09/063,551
• Time in Patent Office: 224 Days
• Field of Search: 514/649, 514/826
• US Class Current: 514/649
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Abstract

The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.

Claims

1. A method of inducing bronchodilation or providing relief of bronchospasm, comprising administering to an individual a quantity of optically pure R-(-) albuterol sufficient to induce said bronchodilation.

2. A method according to claim 1, wherein the albuterol comprises at least 90% by weight of the R(-) isomer and not more than 10% by weight of the S(+) isomer.

3. A method according to claim 1, wherein the albuterol comprises at least 99% by weight of the R(-) isomer and 1% or less by weight of the S(+) isomer.

4. A method according to claim 1, wherein the optically pure R(-) albuterol is administered by inhalation.

5. A method according to claim 4, wherein the optically pure R(-) albuterol is administered in an amount of about 30 μ

g to about 90 μ

g.

6. A method according to claim 1, wherein the optically pure R(-) albuterol is administered orally.

7. A method according to claim 6, wherein the optically pure R(-) albuterol is administered in an amount of about 1 mg to about 8 mg.

8. A method according to claim 6, wherein the optically pure R(-) albuterol is administered as a syrup.

9. A method according to claim 7, wherein the optically pure R(-) albuterol is administered as a syrup.

10. A method of inducing bronchodilation or providing relief of bronchospasm while reducing the concomitant liability of adverse effects associated with racemic albuterol, comprising administering to an individual a quantity of optically pure R-(-) albuterol sufficient to induce said bronchodilation while simultaneously reducing said adverse effects.